The current scientific landscape reflects the urgency to advance therapeutic interventions with over 100 ongoing clinical trials. Heart failure treatment is affected by CA phenotype with poor tolerance of otherwise frequently used medications. Treating comorbidities including atrial fibrillation and valvular disease remains a challenge in CA, driven by technical difficulties and uncertain outcomes. Tafamidis is the first ATTR-stabilizer approved with a rapidly growing rate of clinical use. In parallel, various new therapeutic classes are in late-stage clinical trials including silencers, antibodies and genetic therapy. Managing CA is a critical challenge for future heart failure care. This review delineates the current standard-of-care and scientific landscape of CA therapy.
Keyphrases
- heart failure
- atrial fibrillation
- clinical trial
- healthcare
- left ventricular
- palliative care
- quality improvement
- current status
- protein kinase
- randomized controlled trial
- single cell
- aortic valve
- cardiac resynchronization therapy
- bone marrow
- open label
- replacement therapy
- percutaneous coronary intervention
- chronic pain
- metabolic syndrome
- coronary artery disease
- glycemic control